search "Genetix & Oculus & India" and see for yourself...June 1 articles. they gotta say something after the close, imo.
India's just the beginning...
hopefully, the company will find it prudent to release "the India project" to its shareholders & potential shareholders after the close...or before the open. in either case, we'll head higher into earnings, imo. good luck.
had to sell at 6.79 to keep from losing my mind...what LTC company can't succeed on demographics alone???
the India partnership is just icing on the cake! imo, this is going to run into earnings & beyond - good luck!
another tidbit (from 5/7 article): In addition to other products in the franchise, Oculus has recently added Celacyn as the only prescription scar management product on the market. The FDA and European approvals of Celacyn followed a successful clinical study showing Celacyn to outperform controls receiving a silicone-based scar product. According to pharmaceutical sales databases for the month of March, Oculus' derm division is selling Alevicyn (NDC# 02670-001-02) and Celacyn (NDC# 02670-001-40) at a quarterly rate of 5,300 units and growing, exceeding the company's forecasted sales ramp.
However, a new, seasoned management team is at the controls; the company has sufficient cash to move forward and likely get to breakeven with the cash from the sales of Ruthigen shares; the company launched a new dermatology division; and a new animal health business is under their control with an expanded distribution network that should quickly ramp sales back into the black.
To take a more granular look at the turnaround, consider Jim Schutz took over as CEO in February 2013 when Oculus founder and former CEO Hoji Alimi (along with board members) went to leadership positions at Ruthigen (RTGN), the novel biotechnology business spun-off from Oculus. Although Schutz held numerous positions at Oculus, including being a director since 2004, it is Schutz that is helping right the ship as top executive. As general counsel of Jomed, Schutz orchestrated the company's sale to Abbot Labs (NYSE:ABT) in 2003. He was also general counsel for Volcano Therapeutics, which is now part of Koninklijke Philips (NYSE:PHG).
Oculus' cash position is solid, especially when compared to its market cap. Adding cash on hand at the end of 2014, a January financing, recent sales, commitments to sell the complete stake in Ruthigen as a result of that company's pending acquisition totals about $11 million in cash and expected cash for Oculus. As of this writing the company's market cap is just south of $13 million. Further, the company has no debt.
would it not????
international expansion should yield tangible results imo